Annual report pursuant to Section 13 and 15(d)

Licensing and Other Arrangements - Takeda (Details)

v3.22.0.1
Licensing and Other Arrangements - Takeda (Details) - USD ($)
 1 Months Ended 12 Months Ended
Nov. 16, 2020
Feb. 28, 2009
Nov. 30, 2006
Dec. 31, 2021
Dec. 31, 2020
Licensing and other arrangements          
Revenue from contracts with customers       $ 36,518,000 $ 27,941,000
Takeda | Collaboration agreement          
Licensing and other arrangements          
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones       16,000,000.0  
Revenue from contracts with customers $ 2,000,000.0     100,000 2,100,000
Contract assets       0 0
Contract liabilities       0 0
Capitalized contract costs       0 0
Takeda | Collaboration agreement | TAK-079          
Licensing and other arrangements          
Maximum eligible milestone payments receivable upon achievement of development, regulatory and commercial milestones     $ 19,000,000.0    
Royalty payment period     13 years 6 months    
Takeda | Collaboration agreement | Other antibodies          
Licensing and other arrangements          
Maximum eligible milestone payments receivable per discovery product candidate   $ 3,300,000      
Royalty payment period   10 years      
Takeda | License Agreement          
Licensing and other arrangements          
Revenue from contracts with customers       $ 100,000 $ 100,000